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Abstract
Background: Reduced forced expiratory volume in one second (FEV1) has been linked to non small cell
lung cancer (NSCLC). However, it is unclear whether all or only certain histological subtypes of NSCLC
are associated with reduced FEV1. Moreover, there is little information on whether gender modifies this
relationship. Using a large tissue registry, we sought to determine the relationship between FEV1 and
subtypes of NSCLC and determine whether this relationship is modified by gender.
Methods: We used data from patients who underwent tumor resection for NSCLC at a teaching hospital
in Vancouver and had various pre-operative clinical measurements including FEV1. We divided the cohort
into quartiles of predicted FEV1 and using both logistic and linear regression modeling techniques
determined whether FEV1 was related to the occurrence of adeno or squamous cell carcinoma in men and
women.
Results: There were 610 patients in the study (36% females). On average, women were more likely to
have adenocarcinoma than were men (72% of all cases of NSCLC in women versus 40% in men; p < 0.001).
In women, there was no significant relationship between FEV1 and the risk of any histological subtypes of
NSCLC. In men, however, there was an inverse relationship between the risk of adenocarcinoma and FEV1
such that the lowest quartile of FEV1 was 47% less likely to have adenocarcinoma compared with the
highest FEV1 quartile (adjusted odds ratio, 0.52; 0.28 to 0.98; p for trend, 0.028). The reverse was observed
for squamous cell carcinoma.
Conclusion:  In individuals undergoing lung resection for NSCLC, the risk of adenocarcinoma and
squamous cell carcinoma of the lung varies as a function of FEV1, independent of smoking intensity in men
but not in women.
Clinical Implications: These data indicate that women are much more susceptible to adenocarcinoma
than are men especially when they have normal or near normal lung function. It may thus be useful to
conduct periodic surveillance chest radiographs in asymptomatic female smokers (or ex-smokers) to
ascertain peripheral nodules or masses before distant metastases occur since adenocarcinomas tend to
metastasize earlier in the disease course than squamous cell carcinomas.
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Background
Lung cancer is now an epidemic in women. Although the
incidence of lung cancer has stabilized in men, there con-
tinues to be a dramatic increase in lung cancer cases in the
female population. In 2003, an estimated 80,100 women
in the United States (US) were diagnosed with lung cancer
and 68,800 died from this disease [1]. In women, lung
cancer has surpassed breast cancer as the leading cause of
cancer mortality in 1987 and now accounts for 25% of all
cancer deaths [1]. In both men and women, cigarette
smoking is the leading causative factor for lung cancer.
Compared to never-smokers, smokers have a 20-fold
increase in the risk for lung cancer [2].
Interestingly, reduced forced expiratory volume in one
second (FEV1), an important indicator of lung function,
has also been linked with lung cancer, independent of the
effects of cigarette smoking [3-5]. A study by Wasswa-
Kintu et al. [6] found that FEV1, in a severity-dependent
manner, was associated with lung cancer incidence and
mortality even after adjustments for smoking intensity
and status. Importantly, they found that even a very mod-
est reduction in FEV1 (within the "normal" range of val-
ues) significantly increased the risk of lung cancer among
current and former female smokers. In men, however, the
increase in risk was much less pronounced. This study,
however, did not include information on histological sub-
types of lung cancer. It is therefore unclear whether the
modifying effects of gender on the relationship between
FEV1 and lung cancer impacted the risk for adenocarci-
noma, squamous cell carcinoma or both. Such informa-
tion would be valuable in gaining a better understanding
of the potential differences (or similarities) in lung cancer
susceptibility between men and women. To investigate
this question, we analyzed data from a large cohort of
individuals who underwent surgical resection for a small
peripheral tumor.
Methods
Study participants
Data were obtained from patients who required surgical
treatment of Stage 1 and II lung cancers at St. Paul's Hos-
pital in Vancouver, Canada between 1978 and 2003. All
resected tumors were examined by board-certified pathol-
ogists, who were unaware of the patient's lung function
measurements at the time of the histological assessment.
The histological subtype was diagnosed on surgical speci-
mens according to the World Health Organization classi-
fication [7]. Because very few patients with small cell
carcinomas undergo surgical resection, we restricted the
analysis to non-small cell lung cancers (NSCLC). For ana-
lytic purposes, bronchoalveolar carcinoma was included
in the adenocarcinoma group.
Clinical variables
As part of their pre-operative work-up, all patients com-
pleted a pulmonary function test that met the standards of
the American Thoracic Society [8]. From this test, FEV1,
forced vital capacity (FVC) and transfer coefficient for car-
bon monoxide (KCO) were determined. We applied a pre-
diction equation to calculate predicted FEV1 values for
each patient [9]. Clinical information including age, gen-
der, height, weight, and tobacco smoke exposure were
also collected pre-operatively. Tobacco smoke exposure
was estimated by using current smoking status, and the
number of cigarettes smoked per day (pack-years of smok-
ing). Arterial blood gas measurements on room air were
also obtained in these patients.
Statistical analysis
Continuous variables were compared using a Student t-
test and dichotomous variables were compared using a
chi-square test. To determine the relationship between
FEV1 and the risk of adeno and squamous cell carcinomas
in both men and women, we divided the groups into
quartiles based on FEV1 within each gender category. We
arbitrarily defined quartile 1 as the category with the high-
est predicted FEV1 and quartile 4 as the category with the
The Relative Risk Of Adeno (A) And Squamous Cell Carci- noma (B) According To Baseline FEV1 Measurement In  Women Who Underwent Tumor Resection For Non-Small  Cell Lung Cancer Figure 1
The Relative Risk Of Adeno (A) And Squamous Cell Carci-
noma (B) According To Baseline FEV1 Measurement In 
Women Who Underwent Tumor Resection For Non-Small 
Cell Lung Cancer. Curves were fitted using a spline tech-
nique.
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lowest predicted FEV1. Using quartile 1 as the referent, we
compared the odds of adenocarcinoma (or squamous cell
carcinoma) across the quartiles of FEV1 in a logistic regres-
sion model. To the crude model, we added age, body mass
index (BMI) and pack-years of smoking as covariates as
they were significantly related to FEV1 and the risk of ade-
nocarcinoma (and squamous cell carcinoma). These vari-
ables were included as both categorical and continuous
variables. As there was no material difference in the
results, for simplicity, we included them as continuous
variables in the final model. To test for a linear increase
(or decrease) in the odds ratios (OR) across the quartiles
of FEV1, we used a chi-square test for trend, which
adjusted for age, BMI and pack-years of smoking. We also
performed a linear regression analysis in which we consid-
ered predicted FEV1 as a continuous variable rather than as
quartiles to test the robustness of the data. We constructed
fitted curves using a cubic spline method to visualize the
results (figures 1 and 2). Similar analyses were performed
using squamous cell carcinomas as the dependent varia-
ble. All analyses were conducted using SAS software ver-
sion 9.1 (SAS Institute, Carey, N.C.) and SPSS version
11.0 (Chicago, IL). Two-tailed P-values less than 0.05
were considered significant. Continuous variables are
expressed as mean ± SD, unless otherwise specified.
Results
In total, there were 640 patients during the study period,
who were diagnosed with NSCLC and who provided
informed consent to use their lung tissue for research pur-
poses. Twenty-two patients (3% of total) were excluded
because they had undifferentiated tumors that could not
be confidently classified into one of the two major histo-
logical subtypes of NSCLC. Additionally, eight patients
were excluded due to insufficient information on the clin-
ical variables of interest (e.g. FEV1). This left 610 patients
for analysis.
The baseline characteristics of these patients are summa-
rized in Table 1. There was a significant difference in the
gender distribution of adenocarcinoma (40% in men vs.
73% in women; p < 0.001) and squamous cell carcinomas
(57% in men vs. 24% in women; p < 0.001). Smoking sta-
tus at the time of surgery was similar between male and
female patients (p = 0.082), though overall, men had
higher pack years of smoking compared with women (p <
0.001). Similarly, there was no difference in age between
men and women (p = 0.496). Male patients had slightly
lower FEV1, FVC and arterial oxygen tension (PaO2) than
did female patients (Table 1).
Table 2 summarizes the unadjusted and adjusted odds
ratios (controlling for covariates which included age, BMI
and cigarette smoking) for adenocarcinoma and squa-
mous cell carcinoma in women across quartiles of FEV1.
In women, at all levels of FEV1, the odds of adenocarci-
noma were much higher than that of squamous cell carci-
noma (figure 1a and 1b). However, the odds did not vary
as a function of FEV1.
In contrast, in men, the histological subtype varied signif-
icantly across the FEV1 quartiles (Table 3). Reduced FEV1
was associated with higher odds for squamous cell carci-
noma, while at higher FEV1 values, adenocarcinomas pre-
dominated. These data did not change significantly when
FEV1 was evaluated as a continuous rather than as a cate-
gorical variable (Figures 2a and 2b). Neither forced vital
capacity nor transfer coefficient for carbon monoxide was
significantly related to NSCLC histological subtypes in
either men or women.
Discussion
The most important and novel finding of the present
study was that in women the risk for adenocarcinoma did
not vary as a function of FEV1. At all levels of FEV1, aden-
ocarcinomas predominated, constituting ~70% of all
NSCLCs in the female population. In men, however, FEV1
made a material difference to the risk for adeno and squa-
The Relative Risk Of Adeno (A) And Squamous Cell Carci- noma (B) According To Baseline FEV1 Measurement In Men  Who Underwent Tumor Resection For Non-Small Cell Lung  Cancer Figure 2
The Relative Risk Of Adeno (A) And Squamous Cell Carci-
noma (B) According To Baseline FEV1 Measurement In Men 
Who Underwent Tumor Resection For Non-Small Cell Lung 
Cancer. Curves were fitted using a spline technique.
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mous cell carcinomas. At reduced FEV1, men were far
more likely to develop squamous cell carcinoma than
adenocarcinomas; the reverse was true when FEV1 was in
the normal or near normal range.
These results are consistent with those reported by Papi et
al. [10] who found that individuals with chronic obstruc-
tive pulmonary disease (COPD) with mildly impaired
FEV1 (~70% of predicted) had a four-fold increase in the
risk for squamous cell carcinoma compared to those with
normal lung function (FEV1, ~93% of predicted). How-
ever, this study could not comment on the potential mod-
ifying effects of gender because they had only 18 female
subjects (representing 13% of the total subjects). We
extend their findings by demonstrating that the risk of
squamous cell carcinoma increases with decreasing FEV1
in men but not in women.
The mechanism(s) responsible for the apparent increase
in the risk of adenocarcinoma in women are largely
unknown. However, several possibilities exist. Firstly,
there may be differences in genetic susceptibility. For
instance, women for unknown reasons have more fre-
quent mutations and transversions in the p53 gene than
do men and aberrations in this gene have been associated
with increased risk of adenocarcinoma [11]. Secondly,
hormonal differences may impart differential risk of lung
cancer between men and women. NSCLCs have been
associated with increased expression of estrogen receptor
β in chromosome 14 [12]. Stimulation of this receptor
may have a role in the up-regulation of CYP1A1 gene. This
latter gene encodes for an enzyme that has an integral role
in the production of polycyclic aromatic hydrocarbons
(Phase 1 enzymes), which may be carcinogenic [13]. Con-
sistent with this notion, female smokers have increased
expression of CYP1A1 than do male smokers [14]. Further
investigation is required to investigate if estrogen has a
causal link to adenocarcinoma by promoting carcinogen-
esis through increased CYP1A1 or other related pathways.
Thirdly, inflammation may play a primary role in the
increased susceptibility of women to adenocarcinoma.
Inflammation has been incited as an important part of the
pathogenesis of certain types of lung cancer. Ardies [15]
suggests that infection or toxic chemicals can incite a vig-
orous inflammatory reaction in the airways, producing
certain by-products that may promote carcinogenesis. In
NSCLC, cyclo-oxygenase 2 (COX-2) gene is over-
expressed in nearly all stages of disease progression [16]
and downstream enzymes of the COX-2 pathway
involved in prostanoid synthesis such as prostaglandin E2
synthase is also up-regulated [17]. This inflammatory
pathway has been implicated in the progression of lung
cancer by inhibiting apoptosis, promoting angiogenesis
and facilitating microinvasion of tumor to adjacent tissue,
leading to tumor growth and metastasis [18,19]. Moreo-
ver, COX-2 activity has been associated with poorer prog-
nosis in NSCLC [20]. Interestingly, Szczeklik and
colleagues showed that in the asthmatic population,
women were five times more likely to have a polymor-
phism in the COX-2 promoter region, -765G>C, com-
pared to men (5% versus 1% frequency). This
Table 1: A Comparison of Baseline Characteristics Between Men and Women With Non-Small Cell Lung Cancer, Who Underwent 
SurgeryContinuous variables are expressed as mean ± SD and dichotomous variables are expressed as % of column totals.
Men N = 388 Women N= 222 P value
Age (years) 64 ± 9 64 ± 10 0.432
BMI (kg/m2) 26 ± 4 24 ± 5 <0.001
PaCO2 (mm Hg) 41 ± 8 40 ± 7 <0.001
PaO2 (mm Hg) 80 ± 22 86 ± 30 <0.001
Pre-bronchodilator FEV1(% predicted) 74 ± 19 85 ± 20 <0.001
Post-bronchodilator FEV1 (% predicted) 77 ± 18 88 ± 20 <0.001
Pre-bronchodilator FVC(% predicted) 86 ± 16 94 ± 18 <0.001
Post-bronchodilator FVC, (% predicted) 90 ± 15 96 ± 18 <0.001
KCO (% predicted) 78 ± 23 75 ± 22 <0.001
Current Smokers (%) 57 64 0.082
Pack Years of Smoking* 45 ± 2 37 ± 2 <0.001
Adenocarcinoma (%) 40 73 <0.001
Squamous cell carcinoma (%) 57 24 <0.001
Size of the tumors (cm) 3.6 ± 1.3 2.7 ± 1.0 0.008
Upper Lobe (%) 56 58 0.153
Middle Lobe or Lingula (%) 3 7 0.153
Lower lobe (%) 28 29 0.153
Multiple lobes (%) 5 3 0.153
* Expressed as geometric mean ± standard deviation
Abbreviations: BMI, body mass index, PaCO2, arterial carbon dioxide tension; PaO2, arterial oxygen tension, FEV1, forced expiratory volume in one 
second, FVC, forced vital capacity; KCO, transfer coefficient for carbon monoxideBMC Pulmonary Medicine 2006, 6:2 http://www.biomedcentral.com/1471-2466/6/2
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polymorphism is associated with increased production of
prostaglandin (PG) E2 and D2 [21]. Indeed, monocytes
cultivated from individuals with the C-C genotype pro-
duce levels of PGE2 and PGD2 that are 25 to 34 fold
higher than that obtained from individuals with the G-G
genotype [22]. The importance of this promoter polymor-
phism in the genesis of NSCLC is unknown.
Gender differences in the incidence of subtypes of NSCLC
may also reflect subtle yet important differences in airway
biology. In an experiment by Van Winkle et al. [23],
female mice exposed to naphthalene, a chemical found in
mainstream and sidestream smoke, were more likely to
suffer airway damage than were male mice. Interestingly,
for largely unclear reasons, the naphthalene-induced lung
damage occurred predominantly in the distal airways,
which is the usual site of adeno but not squamous cell car-
cinomas.
Adenocarcinomas tend be more peripherally located than
are squamous cell carcinomas [2]. As such, patients are
often asymptomatic until distant metastases occur. Unfor-
tunately, by then, curative resection is not feasible. Our
data indicate that women are much more susceptible to
adenocarcinoma than are men especially when they have
normal or near normal lung function. It may thus be use-
ful to conduct periodic surveillance chest radiographs in
asymptomatic female smokers (or ex-smokers) to ascer-
tain peripheral nodules or masses before distant metas-
tases occur. A large clinical study is needed to validate this
notion and to determine the cost-effectiveness of this
approach.
There are several limitations to the current study. Firstly,
because individuals with severely impaired FEV1 do not
usually undergo surgical resection for their lung cancer,
the relationship between FEV1 and various cell types of
lung cancer in individuals with FEV1 less than 50% of pre-
dicted remains unknown. Secondly, we did not have data
for individuals with advanced stage lung cancers as these
patients usually do not undergo surgery for their disease.
However, there is no material reason to believe that inclu-
sion or exclusion of such patients would change the find-
ings of this study. Thirdly, we did not have data on small
cell carcinoma because this type of lung cancer metasta-
sizes very early on in the disease course and as such is not
usually amenable to surgical resection. The effect of gen-
der on the relationship between small cell carcinoma and
FEV1 remains unknown.
In summary, the present study demonstrates that the risk
of adeno- and squamous cell carcinoma of the lung varies
as a function of FEV1, independent of smoking intensity
in men but not in women. In women undergoing lung
Table 2: The Relative Odds for Adeno and Squamous Cell Carcinoma In Women Across Different Categories of Lung FunctionThe 
cells contain odds ratio (OR) and the 95% confidence intervals
Quartile of FEV1 1 2 3 4 Trend Test (p value)†
Range of FEV1 (% predicted) 103 to 149 88 to 102 74 to 88 43 to 74
Number of subjects 55 56 55 56
Unadjusted Odds for Adenocarcinoma 1 (reference) 0.83 (0.33–2.05) 0.35 (0.14–0.81) 0.75 (0.31–1.84) 0.216
Adjusted Odds for Adenocarcinoma* 1 (reference) 0.94 (0.36–2.48) 0.44 (0.18–1.09) 0.88 (0.34–2.32) 0.448
1 (reference)
Unadjusted Odds for Squamous Cell Carcinoma 1 (reference) 0.86 (0.32–2.32) 3.00 (1.25–7.18) 1.23 (0.48–3.13) 0.194
1 (reference)
Adjusted Odds for Squamous Cell Carcinoma* 1 (reference) 0.71 (0.25–2.06) 2.19 (0.85–5.61) 0.92 (0.33–2.54) 0.567
*Adjusted for age, body mass index and pack-years
†p-value for linear trend of increasing (or decreasing) odds ratio from quartile 1 to quartile 4
Table 3: The Relative Odds for Adeno and Squamous Cell Carcinoma In Men Across Different Categories of Lung FunctionThe cells 
contain odds ratio (OR) and the 95% confidence intervals
Quartile of FEV1 1 2 3 4 Trend Test (p value)†
Range of FEV1 (% predicted) 89 to 120 78 to 89 64 to 78 27 to 64
Number of Subjects 97 97 97 97
Unadjusted Odds for Adenocarcinoma 1 (reference) 0.88 (0.50–1.55) 0.55 (0.31–1.00) 0.48 (0.27–0.86) 0.004
Adjusted Odds for Adenocarcinoma* 1 (reference) 0.78 (0.43–1.44) 0.59 (0.32–1.09) 0.52 (0.28–0.98) 0.028
Unadjusted Odds for Squamous Cell Carcinoma 1 (reference) 1.28 (0.73–2.25) 1.79 (1.01–3.17) 2.35 (1.31–4.20) <0.001
Adjusted Odds for Squamous Cell Carcinoma* 1 (reference) 1.43 (0.78–2.63) 1.65 (0.90–3.03) 2.09 (1.12–3.90) 0.019
*Adjusted for BMI, age and pack-years
†p-value for linear trend of increasing (or decreasing) odds ratio from quartile 1 to quartile 4Publish with BioMed Central    and   every 
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resection for cancer, adenocarcinoma predominates
across all levels of FEV1. These data raise the possibility
that there are fundamental differences in the airway biol-
ogy between women and men, which confer increased
susceptibility of adenocarcinoma for female smokers.
Given that the incidence of lung cancers continue to rise
in women, it is imperative to further investigate these gen-
der differences such as the role of inflammation as well as
hormonal, molecular and the genetic factors to explain
why women are more prone to develop adenocarcinoma.
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